Skip to main content
main-content

12.05.2017 | Original Article | Ausgabe 11/2017

World Journal of Urology 11/2017

Population-based study of grade progression in patients who harboured Gleason 3 + 3

Zeitschrift:
World Journal of Urology > Ausgabe 11/2017
Autoren:
Fanny Sampurno, Arul Earnest, Jeremy Millar, Mark Frydenberg, Declan Murphy, Warwick Delprado, Sue Evans
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00345-017-2047-z) contains supplementary material, which is available to authorized users.

Abstract

Purpose

This study aimed to evaluate (1) the time interval between a decision to commence on active surveillance (AS) and grade progression in community practice; (2) factors predicting grade progression in localised prostate cancer (CaP) patients apparently undergoing AS.

Methods

Data from the Prostate Cancer Outcomes Registry—Victoria were used to analyze men with Gleason 3 + 3 CaP or less who had at least one repeat biopsy. Unadjusted and adjusted 5-year Kaplan–Meier survival curves were used to assess the time to grade progression. Both univariate and multivariate analyses for grade progression were performed using Cox proportional hazards.

Results

The cohort included 951 men. Overall, 39% of men had Gleason grade reclassified to a higher risk disease state with median of 2.2 years [IQR 1.2–3.7 years]. Men who harboured cT2 disease were 30% more likely to have upgrading compared to men with cT1 disease (adjusted HR: 1.3, 95% CI 1.0–1.6, p = 0.048). Half of the men with cT2 in our cohort had their Gleason grade reclassified within 1.6 years from diagnosis as compared with 2.7 years for the cT1 group. The presence of percentage of core involvement >25.0% and a PSA velocity of >1.01 ng/mL/year remained significant for a higher progression rate. The adjusted HR: 1.6; 95% CI [1.2–2.3], p = 0.004; adjusted HR: 1.6, 95% CI [1.2–2.4], p = 0.021, for percent of core involvement of 25.1–37.5%, and ≥37.6%, respectively. The adjusted HRs and p value associated with PSA velocity were 1.5; 95% CI [1.1–2.1], p = 0.016 and 1.6; 95% CI [1.2–2.3], p = 0.003 for PSA velocity values of 1.01–2 ng/mL per year and >2 ng/mL per year, respectively. Men who were diagnosed in regional hospital and subsequently had biopsy in metropolitan hospital were twice at risk of having Gleason upgrade compared to those whom both diagnostic and surveillance biopsies were carried out in metropolitan hospitals (adjusted HR: 1.9; 95% CI 1.1–3.3, p = 0.029).

Conclusions

When placing men on AS and considering time to histologic progression, clinicians should pay particular attention to the likely accuracy of the diagnostic specimen, their tumour stage, volume of tumour (percent of core involvement), and rising PSA. Those diagnosed with T2 disease and had >25.0% of core involvement, and a PSA velocity greater than 1 ng/mL per year is at particular risk for more rapid disease progression and, for this reason, should be counselled on the importance of following the recommended surveillance regimen. For half of these men, their disease will have ‘progressed’ according to biopsy results in 2 years.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (DOCX 27 kb)
345_2017_2047_MOESM1_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 11/2017

World Journal of Urology 11/2017 Zur Ausgabe
  1. Sie können e.Med Gynäkologie & Urologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Urologie

Meistgelesene Bücher in der Urologie

2016 | Buch

Anogenitale Hautkrankheiten

Erkennen, Befunden, Behandeln

Hautkrankheiten im Bereich Genitale werden werden oft erstmals von einem Facharzt beobachtet, der sich mit anderen genitalen Beschwerden beschäftigt – der Urologe bei Männern oder der Gynäkologe bei Frauen. Dieses Buch schult den Blick für anogenitale Dermatosen und gibt Tipps zur Therapie.

Herausgeber:
Walter Krause, Isaak Effendy

2015 | Buch

Inkontinenz- und Deszensuschirurgie der Frau

Harninkontinenz ist eines der häufigsten Symptome in der Urologie und Gynäkologie. OP-Atlas, unverzichtbarer Ratgeber, kompaktes Nachschlagewerk in einem: Mithilfe dieses Buches werden Sie Spezialist in Sachen Inkontinenz- und Deszensuschirurgie.

Herausgeber:
Rainer Hofmann, Uwe Wagner

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Urologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise